Table 2.

Multivariate analysis for differences in sex, age, and doses; reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine.

	Female (reference: male)				Age (unit change: one year older)				Dose 2 (reference: dose 1)
Reactogenicity	Odds ratio	95% CI		p value	Odds ratio	95% CI		p value	Odds ratio	95% CI		p value
pain (injection site)	1.48	1.26	1.73	<0.001	0.99	0.98	1.00	0.001	0.82	0.70	0.95	0.010
swelling	1.42	1.27	1.59	<0.001	0.98	0.98	0.99	<0.001	1.71	1.54	1.90	<0.001
burning sensation	1.56	1.39	1.75	<0.001	0.97	0.97	0.98	<0.001	1.54	1.38	1.71	<0.001
redness	1.58	1.38	1.82	<0.01	0.98	0.98	0.99	<0.001	2.04	1.80	2.32	<0.001
induration	1.27	1.10	1.46	0.001	1.00	1.00	1.01	0.163	1.18	1.04	1.34	0.012
itching	3.66	2.99	4.48	<0.001	1.01	1.00	1.01	0.070	1.76	1.52	2.05	<0.001
fatigue	1.47	1.31	1.66	<0.001	0.99	0.98	0.99	<0.001	7.18	6.43	8.02	<0.001
muscle pain	1.59	1.42	1.77	<0.001	0.97	0.97	0.98	<0.001	0.95	0.86	1.05	0.334
headache	2.46	2.16	2.81	<0.001	0.99	0.98	0.99	<0.001	5.43	4.80	6.14	<0.001
fever	1.80	1.55	2.09	<0.001	0.97	0.96	0.97	<0.001	27.38	22.00	34.06	<0.001
chills	1.88	1.61	2.19	<0.001	0.98	0.97	0.99	<0.001	16.49	13.53	20.11	<0.001
joint pain	2.02	1.73	2.35	<0.001	0.98	0.98	0.99	<0.001	8.49	7.21	9.99	<0.001
nasal discharge	1.71	1.12	2.63	0.014	1.01	1.00	1.03	0.152	1.46	1.01	2.11	0.046